<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">As a derivative of chloroquine, hydroxychloroquine has similar efficacy and few adverse reactions. Based on its characteristics of immunomodulation, antithrombotic activity, and improved inflammation, hydroxychloroquine has been used in the clinical treatment of systemic lupus erythematosus [
 <xref ref-type="bibr" rid="CR63">63</xref>]. Hydroxychloroquine has been shown to have anti-SARS-CoV activity in vitro [
 <xref ref-type="bibr" rid="CR64">64</xref>], and it is clinically safer than chloroquine [
 <xref ref-type="bibr" rid="CR65">65</xref>, 
 <xref ref-type="bibr" rid="CR66">66</xref>]. Some clinical studies have found that after treatment with hydroxychloroquine, the viral load significantly decreases or even disappears, and azithromycin can enhance the antiviral effect [
 <xref ref-type="bibr" rid="CR67">67</xref>, 
 <xref ref-type="bibr" rid="CR68">68</xref>].
</p>
